MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	9/29/2005 5:31:47 PM
	of 1826

Guilford Pharmaceuticals Stockholders Vote to Approve MGI PHARMA Merger Thursday September 29, 5:27 pm ET BALTIMORE, Sept. 29 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (Nasdaq: GLFD - News) today announced that its stockholders approved the merger transaction pursuant to which Guilford will become a wholly-owned subsidiary of MGI PHARMA, INC. (Nasdaq: MOGN - News), an oncology and acute care focused biopharmaceutical company located in Bloomington, Minnesota. The transaction is expected to be completed on October 3, 2005. Under the terms of the transaction, each share of Guilford common stock will be exchanged for $1.125 in cash and .1103 of a share of MGI PHARMA common stock. The share exchange ratio is based on an average closing price of $23.80, determined over the five day trading period ending three trading days prior to closing. The average price was within the collar set forth in the Merger Agreement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next